Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
High-dose chemotherapy followed by autologous (the patient's own) peripheral blood
(circulating blood) stem cell (cells that divide to form white cells, red cells and cells
that help clot) transplantation is a conventional treatment for patients with lymphoma
(cancer of lymph glands) and Hodgkin's disease (cancer of lymph glands) after first relapse
(recurrence of disease). For patients who did not have a complete response after traditional
chemotherapy, the chance is high that the tumor will return even after high-dose
chemotherapy. To improve the response and decrease the chance of relapse, doctors have used
rituximab, an antibody that kills lymphoma cells, both before and after transplantation.
These doctors have reported that more patients had control of the tumor for an extended
period of time using rituximab with high-dose chemotherapy with autologous stem cell
transplantation. How widely this is applicable is not known.
The purpose of this clinical research trial is to confirm that there is a good control of
tumor in patients with lymphoma or Hodgkin's disease treated with rituximab and conventional
stem cell transplantation.
Phase:
N/A
Details
Lead Sponsor:
Baylor College of Medicine
Collaborators:
Center for Cell and Gene Therapy, Baylor College of Medicine The Methodist Hospital Research Institute The Methodist Hospital System